Relapsing-remitting MS: Relapse rates with oral therapies

Key clinical point: Relapse rates are comparable for patients with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod, dimethyl fumarate, or teriflunomide.

Major finding: After 2 years of treatment initiation, the estimated mean annualized relapse rates were 0.13 (95% confidence interval, 0.04-0.43) for fingolimod, 0.09 (95% confidence interval, 0.03-0.26) for dimethyl fumarate, and 0.11 (95% confidence interval, 0.04-0.35) for teriflunomide.

Study details: The study used inverse probability weighing to compare the efficacy of fingolimod (n=295), dimethyl fumarate (n=227), and teriflunomide (n=107) treatment for at least 24 months in patients with RRMS identified from the Austrian MS Treatment Registry.

Disclosures: The study was funded by Kepler Universitätsklinikum Linz. S Kalcher and E Kvas declared no conflicts of interest. Other authors reported ties with one or more pharmaceutical companies.

Citation: Guger M et al. J Neurol. 2020 Apr 3. doi: 10.1007/s00415-020-09811-6.

Key clinical point: Relapse rates are comparable for patients with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod, dimethyl fumarate, or teriflunomide.

Major finding: After 2 years of treatment initiation, the estimated mean annualized relapse rates were 0.13 (95% confidence interval, 0.04-0.43) for fingolimod, 0.09 (95% confidence interval, 0.03-0.26) for dimethyl fumarate, and 0.11 (95% confidence interval, 0.04-0.35) for teriflunomide.

Study details: The study used inverse probability weighing to compare the efficacy of fingolimod (n=295), dimethyl fumarate (n=227), and teriflunomide (n=107) treatment for at least 24 months in patients with RRMS identified from the Austrian MS Treatment Registry.

Disclosures: The study was funded by Kepler Universitätsklinikum Linz. S Kalcher and E Kvas declared no conflicts of interest. Other authors reported ties with one or more pharmaceutical companies.

Citation: Guger M et al. J Neurol. 2020 Apr 3. doi: 10.1007/s00415-020-09811-6.

Key clinical point: Relapse rates are comparable for patients with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod, dimethyl fumarate, or teriflunomide.

Major finding: After 2 years of treatment initiation, the estimated mean annualized relapse rates were 0.13 (95% confidence interval, 0.04-0.43) for fingolimod, 0.09 (95% confidence interval, 0.03-0.26) for dimethyl fumarate, and 0.11 (95% confidence interval, 0.04-0.35) for teriflunomide.

Study details: The study used inverse probability weighing to compare the efficacy of fingolimod (n=295), dimethyl fumarate (n=227), and teriflunomide (n=107) treatment for at least 24 months in patients with RRMS identified from the Austrian MS Treatment Registry.

Disclosures: The study was funded by Kepler Universitätsklinikum Linz. S Kalcher and E Kvas declared no conflicts of interest. Other authors reported ties with one or more pharmaceutical companies.

Citation: Guger M et al. J Neurol. 2020 Apr 3. doi: 10.1007/s00415-020-09811-6.